01 / THE ARGUMENT
Two budgets describe two different businesses
A dialysis expansion proposal arrives with visible assets, staffing requirements and anticipated sessions. A prevention proposal arrives with uncertain future events that might never occur. That asymmetry can make capital committees favor treatment capacity even when better upstream care is strategically attractive. My thesis is that kidney prevention needs its own investment case, evaluated beside capacity expansion and protected from the demand assumptions embedded in the existing service line.
The two capabilities serve different obligations. People already requiring dialysis need dependable capacity now. Earlier-stage patients need a pathway that identifies kidney risk, confirms the diagnosis, supports appropriate treatment and closes monitoring gaps. The capital decision is about the next increment of resources. It should not be framed as withdrawing necessary services to fund an unproven promise of future savings.
02 / THE ARGUMENT
The newest signal is a recognition problem
A JAMA Cardiology research letter published on 23 September 2026 analyzed 5,797 FINEARTS-HF participants with available kidney measurements. It classified 2,348, or 40.5%, as having previously undiagnosed CKD; 41.3% of that subgroup was identified through urine albumin-to-creatinine ratio alone. This was exploratory research in heart failure with ejection fraction at least 40%. A single albuminuria measurement, investigator-reported history and residual confounding limit interpretation. It is not a population prevalence estimate or randomized proof that screening improves outcomes. [1]
For a business, the useful hypothesis is that a registry built only from diagnosis codes may miss patients who already generate laboratory evidence of risk. That hypothesis can be audited locally. The immediate investment would purchase reliable identification and clinical follow-through, rather than a promised number of prevented dialysis starts. Diagnostic confirmation remains a clinician's responsibility; an automated flag should initiate review, not become an unquestioned disease label.
03 / THE ARGUMENT
Separate preservation of function from avoided dialysis
In the 2026 FIND-CKD randomized trial, 1,584 adults with albuminuric CKD without diabetes received finerenone or placebo on background renin–angiotensin system inhibition. Annual eGFR decline through month 32 averaged −3.3 versus −4.0 mL/min/1.73 m², a difference of 0.7 (95% CI 0.3–1.1). The secondary kidney-only composite had a hazard ratio of 0.78 (95% CI 0.60–1.01). Hyperkalemia occurred in 17.0% versus 13.3%. The primary finding supports slower functional decline in the enrolled population; it does not establish an independently significant reduction in the kidney-only composite. [2]
The capital implication is conditional. A service able to identify suitable patients, deliver clinician-approved treatment and complete monitoring may change future disease trajectories. The size and timing of that change must be estimated from local risk, uptake, persistence and competing outcomes. A mean eGFR-slope difference cannot be multiplied mechanically into dialysis chairs avoided, and a study population cannot be treated as an automatic expansion of local prescribing eligibility.
04 / THE ARGUMENT
Combination evidence creates workflow demands
The 2025 CONFIDENCE randomized trial compared finerenone plus empagliflozin with either agent alone in CKD with type 2 diabetes on background renin–angiotensin system inhibition. At 180 days, the relative UACR reduction was 29% greater than with finerenone alone and 32% greater than with empagliflozin alone. The primary endpoint was albuminuria, not kidney failure, survival or dialysis use. Short-term tolerability in a monitored trial does not remove the need for clinical selection and follow-up. [3]
My operating inference is that treatment complexity raises the value of coordination. A prescription-only initiative can leave laboratory scheduling, result review and escalation distributed across several teams, with nobody responsible for completion. A credible prevention service therefore requires a closed task loop: each requested test has a due date, each result reaches an accountable clinician, and each unresolved exception remains visible until addressed. That capability can be useful across therapies without claiming that the service itself has trial-proven efficacy.
05 / THE ARGUMENT
Model value without counting the same dollar twice
For a purchaser bearing total medical costs, a proposed present-value model is V = Σt[(ΔKt × Ckt + ΔHt × Cht) − Pt − Mt] / (1 + r)^t − F. ΔK and ΔH are incremental kidney-replacement and hospitalization episodes avoided against a defined counterfactual; C values are attributable costs; P is prevention delivery and treatment expenditure; M is monitoring expenditure; F is implementation investment. The model requires mutually exclusive event accounting or explicit adjustment for overlapping costs.
This is an analytical framework, not an empirical forecast. For a dialysis provider paid per session, an avoided start may reduce revenue while leaving rent, equipment and minimum staffing costs unchanged. Only genuinely avoidable costs belong in a cash-saving claim. A shared-risk contract could align those incentives, but its economics depend on attribution, payment terms and how long the organization retains responsibility. One stakeholder's avoided expenditure is not automatically another stakeholder's distributable saving.
06 / THE ARGUMENT
Buy a measurable prevention capability
Consider an integrated provider proposing a regional dialysis facility while carrying financial responsibility for a defined CKD population. The chief medical officer and chief financial officer should jointly commission a prevention pilot before finalizing incremental capacity. Its bounded budget covers a registry, clinical review time, care coordination, laboratory completion and approved treatment access. Existing dialysis operations retain their service budget and clinical capacity obligations.
The comparison should be a contemporaneous population receiving the existing pathway, with baseline kidney risk and access barriers explicitly balanced; randomizing a phased rollout would strengthen causal interpretation. Early measures assess whether eligible people are found and followed safely. Later assessment examines kidney-function trajectories, admissions and kidney-replacement starts. Capacity scenarios should incorporate uncertainty, including a case in which prevention improves care but produces no measurable near-term reduction in dialysis demand.
07 / THE ARGUMENT
A capital decision that can be reversed
The prevention thesis fails operationally if screening generates a queue that clinicians cannot resolve, monitoring becomes unreliable, or costs rise without improving the chosen clinical and access measures. It fails as a capacity thesis if credible local projections still show demand exceeding available dialysis capacity under successful prevention. Those are different failure tests and should lead to different decisions.
Executives should fund prevention in stages and preserve the option to expand treatment capacity when evidence warrants it. The next approval should purchase a functioning clinical pathway and a better demand forecast. It should not capitalize assumed savings from a surrogate endpoint. A kidney business becomes more resilient when its plan can support both slower progression and continued demand for excellent dialysis care.
FROM THESIS TO ALLOCATION
A bounded business case
Proposed operating design and evaluation criteria. These are the author’s recommendations, not outcomes established by the cited studies.
- Decision
- Approve a capped regional prevention pilot and require its demand scenarios in the next dialysis-capacity review.
- Accountable owner
- Chief medical officer and chief financial officer, with a named kidney-program clinical lead.
Delivery workflow
- Audit diagnosis, eGFR and albuminuria information for a clearly defined attributed population.
- Route possible CKD and missing information for clinician review and appropriate confirmation.
- Provide treatment-access support and a documented monitoring and escalation owner.
- Compare outcomes and total costs with the current pathway; refresh capacity forecasts using explicit uncertainty.
Economic logic
Maintain separate purchaser and provider ledgers. Count only attributable avoided episodes and avoidable costs, include prevention and monitoring expenditure, and do not convert biomarker changes directly into cash savings.
Success measures
- Confirmed risk identification
- Completed clinical follow-up
- Monitoring completion and safety escalation
- Kidney-function trajectory
- Risk-adjusted admissions and kidney-replacement starts
- Total cost within the agreed budget horizon
Stop or redesign when
Pause enrollment or expansion when clinical review or monitoring capacity is inadequate; reconsider the service if it adds cost without the prospectively defined improvement. Preserve dialysis expansion when demand and access evidence support it.
THE EVIDENCE LEDGER
What each study can support
Study findings and limitations are kept separate from the operating proposals above.
| Study | Design | Verified finding | Boundary |
|---|---|---|---|
| [1] JAMA Cardiology | Exploratory secondary analysis of FINEARTS-HF, published as a research letter. | Among 5,797 evaluable participants, 2,348 (40.5%) met the analysis's undiagnosed-CKD definition; UACR alone identified 41.3% of that subgroup. | Heart-failure trial population, one-time UACR, investigator-reported history and residual confounding; not a screening intervention trial. |
| [2] The New England Journal of Medicine | Randomized placebo-controlled trial in 1,584 adults with albuminuric CKD without diabetes. | Total eGFR-slope difference at 32 months: 0.7 mL/min/1.73 m²/year (95% CI 0.3–1.1); kidney-only composite confidence interval crossed 1. | Selected albuminuric population; primary endpoint was eGFR slope; adverse events and background therapy matter for implementation. |
| [3] The New England Journal of Medicine | Randomized double-blind three-arm trial; primary endpoint was relative change in UACR at 180 days. | Combination therapy produced a UACR reduction 29% greater than finerenone alone and 32% greater than empagliflozin alone. | Short follow-up and surrogate endpoint; no demonstrated dialysis-use or cash-saving result. |
FOLLOW THE SOURCE
Sources and editorial method
Original strategic interpretation of selected peer-reviewed evidence searched through 27 September 2026, including a paper published 23 September; not an exhaustive latest-paper ranking, a journal publication, patient-specific advice or investment advice. Azis R. Dabas is the editorial author, not an author of the cited studies. Clinical eligibility, product authorization and payment rules need separate local review.
Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial
John W. Ostrominski, Finnian R. Mc Causland, Brian L. Claggett, et al.. JAMA Cardiology. .
DOI: 10.1001/jamacardio.2026.3507 · Primary verification record
No matching Consensus record was available at review; the primary journal record was verified.
Finerenone in Persons with Chronic Kidney Disease without Diabetes
Hiddo J. L. Heerspink, Brendon L. Neuen, Rajiv Agarwal, et al.; FIND-CKD Investigators. The New England Journal of Medicine. .
DOI: 10.1056/NEJMoa2604625 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 11. Counts are a dated index snapshot, not an assessment of study quality.
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
Rajiv Agarwal, Jennifer B. Green, Hiddo J. L. Heerspink, et al.. The New England Journal of Medicine. .
DOI: 10.1056/NEJMoa2410659 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 190. Counts are a dated index snapshot, not an assessment of study quality.
Affiliations and study authorship belong to the cited researchers. No institutional affiliation or endorsement of this editorial analysis is implied. Publication dates use the verified source precision; a month-only date identifies an issue month.